Viewing all links from the source for category: Pharma/Biotech

01/09/2025

PYC Therapeutics: POLYCYSTIC KIDNEY DISEASE PROGRAM – PRESENTATION OF SAFETY DATA AT ANZSN

29/08/2025

United for innovation: AusBiotech and Medicines Australia celebrate Catalyst outcomes, further strengthen industry collaboration

Starpharma: $3.7 Million R&D Tax Incentive Receiv ed

28/08/2025

Invion exec highlights potential upside with cancer treatment trials

27/08/2025

Emyria to Expand Perth Clinic to Meet Growing Demand and Support National Roll-Out

AMPLIA SHARE PURCHASE PLAN RAISES A$2.65 MILLION

Avecho: Waking the sleeping giant

26/08/2025

Botanix appoints Dr Patricia Walker to the Board

Noxopharm: HERACLES clinical trial – Update #3

25/08/2025

SPONTAN®Achieves 100% Patient Satisfaction in Post-Prostatectomy EDCase Series

18/08/2025

Lumos Diagnostics partners with PRO-spectus to accelerate market access and reimbursement for Febri-Dx

15/08/2025

CSL’s Venofer finally faces generic competition as FDA clears copycats from Viatris, Sandoz and Amphastar

Orthocell: Commercialisation on Remplir into US$1.6bn US market continues to build momentum

14/08/2025

Nyrada Appoints Consultant Cardiologist for Phase IIa Xolatryp™ Trial

13/08/2025

RECCE ® 327 Topical Gel Highly Effective and Accelerated Wound Healing for Burn Wounds in Rat Infection Models

12/08/2025

Noxopharm: HERACLES clinical trial – Update #2

11/08/2025

FDA announces resolution of the IV Saline Solutions Shortage

07/08/2025

Cartherics unveils state-of-the-art cleanroom facility for cell therapy manufacturing

Nyrada: Positive Final Review of Nyrada Phase I Clinical Trial

Percheron Therapeutics: RESEARCHERS AT UNIVERSITY OF TEXAS PUBLISH NEW PRECLINICAL DATA SHOWING ACTIVITY OF HMBD-002 IN TRIPLE-NEGATIVE BREAST CANCER

Amplia Therapeutics: Positive ACCENT Trial Topline Data Released

MAYNE PHARMA RECEIVES ADDITIONAL NOTICE OF INTENTION TO TERMINATE FROM COSETTE

Novo Nordisk faces investor lawsuit over ‘false and misleading’ semaglutide sales projections

Pfizer’s embattled obesity program loses another GLP-1 over poor data and strong competition

06/08/2025

Noxopharm: US company demonstrates strong Sofra™ potential

Introducing Monash Ventures – the venture and investment arm of Monash University

04/08/2025

Medicines Australia: United for innovation: AusBiotech and Medicines Australia celebrate Catalyst outcomes, further strengthen industry collaboration

Nyrada: Nyrada Successfully Raises $8.25 Million via Placement

31/07/2025

Breakthrough Therapies: How ASX Innovation Leaders Are Riding the Global Biotech Renaissance

Noxopharm: June 2025 Quarterly Activities Report and Appendix 4C

30/07/2025

Syntara: First participant dosed in SNT-9465 phase 1a/b trial targeting hpyertrophic scars

LTR Pharma: Quarterly Activities/Appendix 4C Cash Flow Report

29/07/2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate – Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Botanix Pharmaceuticals Quarterly activity report and 4c quarterly cash flow report

Emyria: Quarterly Activities Report | June 2025

Noxopharm: HERACLES clinical trial – Update #1

Clarity: Clarity successfully completes $203 million institutional placement

28/07/2025

The cannabis factory: How one doctor wrote 72,000 scripts in two years

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

24/07/2025

Fixing cracks in the artificial intelligence drug development pipeline

Study of GLP-1 guidelines for teens points to potential for influence from drugmakers

Telix subpoenaed by US regulator over cancer therapy

23/07/2025

Sanofi’s $2.5b deal to buy biotech with rights to Aussie vaccine invention

22/07/2025

First treatment option SKYCLARYS(TM) (omaveloxolone) for Australian’s diagnosed with ‘neurogenerative disease’ Friedreich ataxia – Biogen Australia

Nyrada: Final Phase I Clinical Trial Patients Dosed and Discharged

21/07/2025

Emyria: Less than Marketable Parcel Sale Facility

Novotech Report: How In-Vivo CAR-T May Reshape Cell Therapy Economics – Novotech

Armitage readies healthtech for sale, tapping Houlihan Lokey

Waiting to get rich from biotech? Don’t hold your breath

Lumos signs binding term sheet for A$5.0 million loan facility